Prev Arrow Stocks

Chemours Company (The) ($CC) Stock Forecast: Up 5.0% Today

Morpher AI identified a bullish signal. The stock price may continue to rise based on the momentum of the good news.

What is Chemours Company (The)?

Chemours Co. (NYSE: CC) operates in titanium technologies, fluoroproducts, and chemical solutions. The stock exhibited strong bullish movement today amidst a variety of insider activities and financial announcements.

Why is Chemours Company (The) going up?

CC stock is up 5.0% on May 11, 2026 16:35

  • The positive sentiment surrounding CC stock's uptrend might be linked to the completion of a Euro-denominated term loan repricing, hinting at potential cost savings for the company.
  • Notable insider stock grants were awarded to directors Courtney Mather, Mary B. Cranston, and Erin N. Kane, potentially boosting investor confidence in the company's growth trajectory.
  • The equity awards given to directors in a non-cash form indicate alignment with shareholders' interests, which could enhance investor trust in the stock.
  • In summary, a mix of favorable financial updates and insider activities likely fueled the bullish movement of CC stock during the day.

CC Price Chart

CC Technical Analysis

CC News

Number of shareholders of Chemours Co. – DUS:2CU

The article, published on TradingView, provides a page specifically for Chemours Co. (DUS:2CU) financials, including general information and data fields for the number of shareholders. It highlights market data provided by ICE Data Services and FactSet, along with SEC filings from Quartr.

https://www.tradingview.com/symbols/DUS-2CU/financials-statistics-and-ratios/number-of-shareholders/

0 News Article Image Number of shareholders of Chemours Co. – DUS:2CU

Chemours (NYSE: CC) director Courtney Mather granted 7,182 stock units

Chemours director Courtney Mather was granted 7,182 stock units on May 6, 2026, which will convert into common shares upon her separation from service on the Board. Following this award, Mather now holds a total of 21,642.7173 stock units. The grant was part of equity compensation and did not involve a cash payment from the director.

https://www.stocktitan.net/sec-filings/CC/form-4-chemours-co-insider-trading-activity-023220f7ffeb.html

1 News Article Image Chemours (NYSE: CC) director Courtney Mather granted 7,182 stock units

The Chemours Company Announces Completion of Euro denominated Term Loan Repricing

The Chemours Company announced the completion of its Euro-denominated term loan repricing. This news was released via a Quantisnow PR, a platform that aggregates market data and news for retail investors. The article also includes recent analyst ratings and details of insider stock grants for several directors of Chemours Company.

https://www.quantisnow.com/insight/the-chemours-company-announces-completion-of-euro-denominated-term-loan-repricing-5813138

2 Missing News Article Image The Chemours Company Announces Completion of Euro denominated Term Loan Repricing

Chemours director granted 7,182 company shares | CC Insider Trading

Chemours (NYSE: CC) director Mary B. Cranston received an equity grant of 7,182 common shares on May 6th, reflecting stock-based compensation. This award, granted at no cash cost, increases her total holdings to 106,830.0129 shares, including deferred stock units and dividend equivalent units, after an adjustment for a previous administrative error. The transaction was reported in a Form 4 filing, indicating an internal compensation event rather than an open-market purchase.

https://www.stocktitan.net/sec-filings/CC/form-4-chemours-co-insider-trading-activity-5e47bdb5f037.html

3 News Article Image Chemours director granted 7,182 company shares | CC Insider Trading

Chemours (NYSE: CC) director Erin Kane granted 7,182 stock units

Chemours (NYSE: CC) director Erin N. Kane was granted 7,182 stock units as board compensation, increasing her total holdings to 74,062.9086 units. These units, which will convert to common stock upon her separation from the board, were granted at $0.00 per unit and represent a routine, non-cash equity award rather than an open-market purchase. This insider transaction was reported on an SEC Form 4 filing.

https://www.stocktitan.net/sec-filings/CC/form-4-chemours-co-insider-trading-activity-d2852b3d4ef6.html

4 News Article Image Chemours (NYSE: CC) director Erin Kane granted 7,182 stock units

Chemours Company (The) Price History

10.03.2026 - CC Stock was up 5.4%

  • Chemours (CC) experienced a strong bullish movement today due to an increased target price and maintained Buy rating by a leading financial institution. This positive outlook reflects confidence in the company's growth potential.
  • The high-performance fluoropolymers (HPF) market is projected to grow, potentially benefiting Chemours given its presence in industrial chemicals, including components for aerospace and automotive industries.
  • Despite the positive forecast and price target increase, Chemours reported a negative net margin and a year-over-year revenue decline, suggesting possible challenges ahead despite the bullish market movement.
  • Ongoing discussions by the EU chemicals agency regarding PFAS chemicals could have implications for Chemours in the future, underscoring regulatory risks in the industry.

07.04.2026 - CC Stock was down 5.2%

  • Chemours (CC) recorded a Q1 loss of US$29 million, raising concerns about its profitability and influencing the bearish market trend.
  • Despite displaying some positive operational advancements, the stock faced a 13% decline due to the market's negative response to adjusted earnings guidance and heightened financial commitments.
  • The company's declaration of a quarterly cash dividend potentially offered some stability, but the focus on margins, revenue growth, and financial pressures contributed to the prevailing bearish outlook.
  • Observers are particularly attentive to Chemours' pricing strategies, operational efficiencies, and ability to navigate geopolitical challenges as they evaluate its future trajectory and market sentiment.

30.02.2026 - CC Stock was down 5.1%

  • Despite a recent 5-day winning streak and reaching a new 52-week high, Chemours stock showed strong bearish movement today.
  • Investor profit-taking following the stock's surge in the past few days could explain the bearish pullback.
  • Concerns from analysts regarding the company's weak operational performance, financial state, and high valuation might have influenced the bearish sentiment.
  • The absence of specific positive developments today likely prompted investors to reassess their positions, resulting in the bearish market trend.

08.03.2026 - CC Stock was down 5.8%

  • The bearish movement in CC's stock today could be attributed to concerns surrounding the ongoing lawsuit with the Cape Fear Public Utility Authority over PFAS contamination in drinking water.
  • Despite a company raising its price target on CC and maintaining an "Outperform" rating, the market may be reacting to uncertainties regarding the impact of ultrashort-chain PFAS compounds on the company's operations.
  • The upsizing and pricing of the $700 million senior notes offering by Chemours could have also influenced the bearish sentiment, as investors may be wary of the company's increased debt burden.
  • The significant increase in stake by SG Americas Securities LLC signals long-term confidence in Chemours, but the market may be focusing more on the immediate challenges the company is facing with regards to environmental issues and financial decisions.

30.03.2026 - CC Stock was up 5.0%

  • The significant stock price appreciation of Chemours (CC) can be attributed to multiple factors:
  • Despite differing views on its valuation, the stock has experienced a surge in price, indicating investor confidence in its future.
  • Investments by Vanguard Capital Management and Vanguard Portfolio Management have further bolstered faith in the company's growth.
  • The recent peak in stock price reflects positive momentum and investor attraction towards Chemours.
  • Concerns raised by Cumberland County about PFAS contamination pose potential risks for Chemours, potentially affecting its future stock performance.

16.03.2026 - CC Stock was up 5.1%

  • Chemours (CC) reached a new 52-week high of $23.20, trading with high volume and significantly above its moving averages, reflecting robust investor interest and positive market sentiment.
  • The increase in Chemours' stock price can be linked to the company's recent strong financial performance, surpassing EPS expectations, despite having certain mixed fundamentals like negative net margin and P/E ratio.
  • The update about Southeast Ohio water authorities securing funds for PFAS treatment upgrades may have had a positive impact on Chemours, given the company's involvement in producing chemicals and solutions relevant for water treatment processes.
  • Despite being labeled as overvalued by some analysts, there appears to be a positive market outlook on Chemours' future prospects, with institutions like UBS raising their price target and reaffirming a "Buy" rating.

09.03.2026 - CC Stock was up 5.6%

  • CC reached a 52-week high at $22.56, marking a 139% increase in the past year, potentially attracting positivity from investors.
  • Mizuho raised CC's price target to $25 from $21, upholding an "Outperform" rating, potentially enhancing investor confidence and influencing the bullish trend.
  • Despite the lawsuit and regulatory challenges, CC's optimistic earnings forecast for 2026 and expected improvements in titanium dioxide EBITDA margins may have outweighed these issues, propelling the stock.
  • The options chain analysis, detailing call and put options expiring in May 2026, possibly signified a bullish outlook among traders, adding momentum to CC's stock.

24.03.2026 - CC Stock was up 5.1%

  • The bullish movement in CC stock today could be attributed to the positive growth outlook for the global fluoropolymer films market, driven by demand in high-performance industries like electronics and automotive.
  • Earth Day petitions urging Chemours to protect the Okefenokee Swamp may have also fueled investor optimism, highlighting the company's dedication to environmental responsibility and sustainability.
  • The forthcoming Q1 financial results announcement on May 5 and the subsequent public webcast on May 6 may be creating anticipation and confidence among investors, contributing to the bullish market activity in CC stock.

01.03.2026 - CC Stock was down 5.0%

  • The bearish movement in Chemours stock today could be attributed to profit-taking by investors after the recent 5-day winning spree, where the stock climbed 22%.
  • Concerns may have arisen among investors about potential legal liabilities and future financial impacts on the company due to the news about a potential new lawsuit against Chemours for PFAS contamination in North Carolina.
  • Despite the positive collaboration with the University of Kansas on sustainable cooling technologies, the overall sentiment from analysts describing the stock as "Very Unattractive" due to weak operating performance and high valuation could have also influenced today's bearish market movement.

06.04.2026 - CC Stock was down 16.0%

  • Today, Chemours experienced a decline in its stock price, possibly due to the company's failure to meet revenue expectations in Q1, reporting $1.38 billion instead of the anticipated $1.40 billion.
  • While announcing a new dividend and achieving a 52-week high were positive developments, the slight revenue miss may have raised uncertainties among investors about the company's future growth.
  • The use of AI models indicating increased downside risk at current levels might have also influenced bearish sentiment, leading some investors to cash in profits or adjust their positions cautiously.
  • The market's response appears to combine profit-taking following recent strong performance and some ambiguity surrounding Chemours' revenue outlook in the short term.

05.04.2026 - CC Stock was up 5.5%

  • CC stock hit a new 52-week high of $27.53, marking a significant 130% year-to-date increase, driven by strong investor confidence and strategic growth measures.
  • The successful $700 million debt issuance to retire existing notes and positive analyst projections regarding enhanced profitability and higher titanium dioxide EBITDA margins have further propelled the optimistic sentiment.
  • Despite concerns raised about potential overvaluation, positive market sentiment, approval of equity plans by shareholders, and the appointment of an independent auditor have all played a role in the stock's upward trend.
  • Strategic decisions, such as the endorsement of the 2026 Equity and Incentive Plan and favorable analyst reviews, are likely factors boosting investor confidence and contributing to the positive momentum in CC stock.

11.04.2026 - CC Stock was up 5.0%

  • The positive sentiment surrounding CC stock's uptrend might be linked to the completion of a Euro-denominated term loan repricing, hinting at potential cost savings for the company.
  • Notable insider stock grants were awarded to directors Courtney Mather, Mary B. Cranston, and Erin N. Kane, potentially boosting investor confidence in the company's growth trajectory.
  • The equity awards given to directors in a non-cash form indicate alignment with shareholders' interests, which could enhance investor trust in the stock.
  • In summary, a mix of favorable financial updates and insider activities likely fueled the bullish movement of CC stock during the day.
i
Disclaimer
Morpher is not liable for the content of the AI investment insights. Like most GPT-powered tools, these summaries may contain AI hallucinations and inaccurate information. Morpher is not presenting you with any investment advice. All investments involve risk, and the past performance of a security, industry, sector, market, or financial product does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. Such decisions should be based solely on an evaluation of their financial circumstances, investment objectives, risk tolerance, and liquidity needs. These summaries do not constitute investment advice.